Oklo stock tumbles as Financial Times scrutinizes valuation
Ceribell, Inc. (NASDAQ:CBLL), a medical device company with impressive gross profit margins of 88%, announced Wednesday that it has amended its corporate supply agreement to designate a new manufacturing partner in Vietnam. According to a statement based on a recent SEC filing, the amendment was entered into on Sunday by Ceribell, Shenzhen Everwin Precision Technology Co., Ltd., and Everwin Precision (Viet Nam) Technology Co., Ltd. The company maintains strong liquidity with a current ratio of 13.3, suggesting robust operational flexibility for such strategic moves.
Under the latest amendment, Everwin Vietnam, a subsidiary of Everwin China, will serve as an agent of Everwin China and provide deliveries of Ceribell’s headband products from its facility in Vietnam. The supply agreement, originally signed in January 2022 and previously amended to extend its term and adjust delivery locations, governs the supply of Ceribell’s small and large headbands on a purchase order basis. It also grants Ceribell broad license rights to product materials necessary for manufacturing and support.
Earlier amendments to the agreement extended its term through December 31, 2027, and provided for deliveries from a facility in Tijuana, Mexico. The company noted that the most recent amendment expands the list of authorized suppliers to include the Vietnam facility.
Ceribell’s common stock is listed on the Nasdaq Global Select Market under the symbol CBLL. The company is incorporated in Delaware and is based in Sunnyvale, California.
This information is based on a press release statement contained in Ceribell’s Form 8-K filing with the Securities and Exchange Commission.
In other recent news, Ceribell Inc reported a 38% year-over-year increase in total revenue for Q2 2025, reaching $21.2 million. Despite this growth, the company recorded a net loss of $13.6 million, or $0.38 per share. In a strategic move, Ceribell announced the appointment of Erica Rogers to its Board of Directors. Rogers, who previously served as CEO of Silk Road Medical, brings over 30 years of experience in the medical device industry. During her tenure at Silk Road, she led the company from a startup to a publicly traded entity with revenue exceeding $175 million. These developments reflect Ceribell’s ongoing efforts to strengthen its leadership team and financial performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.